论文部分内容阅读
现将近期日本治疗慢性乙型肝炎的几种新疗法的研究情况,综合介绍如下。一、抗病毒剂[1～8、19、20] 抗病毒剂的应用,旨在清除体内的HBV以切断体内的持续感染。然而,至今尚无针对HSV的特异疗法。已知HBe抗体阳性的慢性肝炎患者较HBe抗原阳性者的预后好得多,且HBe抗体阳性的母亲不导致母婴垂直感染,据此可认为促使慢性肝炎患者HBe抗原向HBe抗体转变是治疗的直接目标。临床实践证明,干扰素和阿糖腺苷能促使这种血清学转变,并能降低与Dane颗粒有关的DNA聚合酶(DNAP)活
Now the recent treatment of chronic hepatitis B in Japan several new research situation, a comprehensive introduction is as follows. Antiviral Agents [1 ~ 8, 19, 20] The use of antiviral agents aims to clear the body of HBV to cut off persistent infections in the body. However, there are no specific therapies for HSV so far. It is known that patients with HBe-positive chronic hepatitis have a much better prognosis than those with positive HBe-positive disease and that HBe-positive mothers do not cause vertical mother-to-infant infection. Therefore, it is considered that the conversion of HBe to HBe in patients with chronic hepatitis is considered to be therapeutic Direct goal. Clinical practice has proved that interferon and vidarabine promote this serological transformation and reduce DNA polymerase (DNAP) activity associated with Dane particles